Cell biology and dynamics of Neuronal Na+/K+-ATPase in health and diseases
Neuronal Na+/K+-ATPase is responsible for the maintenance of ionic gradient across plasma membrane. In doing so, in a healthy brain, Na+/K+-ATPase activity accounts for nearly half of total brain energy consumption. The α3-subunit containing Na+/K+-ATPase expression is restricted to neurons. Heteroz...
Saved in:
Published in | Neuropharmacology Vol. 169; p. 107461 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.06.2020
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Neuronal Na+/K+-ATPase is responsible for the maintenance of ionic gradient across plasma membrane. In doing so, in a healthy brain, Na+/K+-ATPase activity accounts for nearly half of total brain energy consumption. The α3-subunit containing Na+/K+-ATPase expression is restricted to neurons. Heterozygous mutations within α3-subunit leads to Rapid-onset Dystonia Parkinsonism, Alternating Hemiplegia of Childhood and other neurological and neuropsychiatric disorders. Additionally, proteins such as α-synuclein, amyloid-β, tau and SOD1 whose aggregation is associated to neurodegenerative diseases directly bind and impair α3-Na+/K+-ATPase activity. The review will provide a summary of neuronal α3-Na+/K+-ATPase functional properties, expression pattern, protein-protein interactions at the plasma membrane, biophysical properties (distribution and lateral diffusion). Lastly, the role of α3-Na+/K+-ATPase in neurological and neurodegenerative disorders will be discussed.
This article is part of the special issue entitled ‘Mobility and trafficking of neuronal membrane proteins’.
•The low Na+ affinity α3 is a neuron specific subunit of Na+/K+-ATPase.•α3-Na+/K+-ATPase laterally diffuses and form clusters on the plasma membrane.•Over 90 mutations affect the gene encoding for α3-Na+/K+-ATPase (ATP1A3).•α3-Na+/K+-ATPase interacts with exogenous α-Synuclein and Amyloid-β. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0028-3908 1873-7064 |
DOI: | 10.1016/j.neuropharm.2018.12.008 |